The amyloid cascade hypothesis: are we poised for success or failure?
E Karran, B De Strooper - Journal of neurochemistry, 2016 - Wiley Online Library
The first description of Alzheimer's disease (AD) was made in 1907 by Alois Alzheimer
(Allgemeine Zeitschrift fur Psyciatrie und Psychisch‐Gerichtliche Medizin 64, 3, 1907) …
(Allgemeine Zeitschrift fur Psyciatrie und Psychisch‐Gerichtliche Medizin 64, 3, 1907) …
Mitochondrial dysfunction in Alzheimer's disease: a biomarker of the future?
Alzheimer's disease (AD) is the most common cause of dementia worldwide and is
characterised pathologically by the accumulation of amyloid beta and tau protein …
characterised pathologically by the accumulation of amyloid beta and tau protein …
Neurobiology of Alzheimer's disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions
J Raskin, J Cummings, J Hardy… - Current Alzheimer …, 2015 - ingentaconnect.com
Background: Alzheimer's disease (AD), the most common form of dementia, is a progressive
neurodegenerative disorder with interrelated molecular, physiological, anatomical …
neurodegenerative disorder with interrelated molecular, physiological, anatomical …
In vivo methods for imaging blood–brain barrier function and dysfunction
WJ Harris, MC Asselin, R Hinz, LM Parkes… - European journal of …, 2023 - Springer
The blood–brain barrier (BBB) is the interface between the central nervous system and
systemic circulation. It tightly regulates what enters and is removed from the brain …
systemic circulation. It tightly regulates what enters and is removed from the brain …
Protective effect of amyloid-β peptides against herpes simplex virus-1 infection in a neuronal cell culture model
Senile amyloid plaques are one of the main hallmarks of Alzheimer's disease (AD). They
correspond to insoluble deposits of amyloid-ß peptides (Aß) and are responsible for the …
correspond to insoluble deposits of amyloid-ß peptides (Aß) and are responsible for the …
Alzheimer disease
AL Calderon-Garcidueñas, C Duyckaerts - Handbook of clinical neurology, 2018 - Elsevier
Alzheimer disease neuropathology is characterized by the extracellular accumulation of Aβ
peptide and intracellular aggregation of hyperphosphorylated tau. With the progression of …
peptide and intracellular aggregation of hyperphosphorylated tau. With the progression of …
Alzheimer's disease and cancer: when two monsters cannot be together
S Majd, J Power, Z Majd - Frontiers in neuroscience, 2019 - frontiersin.org
Alzheimer's disease (AD) and cancer are among the leading causes of human death around
the world. While neurodegeneration is the main feature of AD, the most important …
the world. While neurodegeneration is the main feature of AD, the most important …
Insulin mediated novel therapies for the treatment of Alzheimer's disease
Alzheimer's disease, a progressive neurodegenerative disorder, is one of the leading
causes of death in the USA, along with cancer and cardiac disorders. AD is characterized by …
causes of death in the USA, along with cancer and cardiac disorders. AD is characterized by …
Glucose tolerance and insulin sensitivity are impaired in APP/PS1 transgenic mice prior to amyloid plaque pathogenesis and cognitive decline
L Macklin, CM Griffith, Y Cai, GM Rose, XX Yan… - Experimental …, 2017 - Elsevier
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by beta-
amyloid (Aβ) deposition, neurofibrillary tangles and cognitive decline. Clinical data suggests …
amyloid (Aβ) deposition, neurofibrillary tangles and cognitive decline. Clinical data suggests …
The involvement of peripheral and brain insulin resistance in late onset Alzheimer's dementia
J Folch, J Olloquequi, M Ettcheto… - Frontiers in aging …, 2019 - frontiersin.org
Nowadays, Alzheimer's disease (AD) is a severe sociological and clinical problem. Since it
was first described, there has been a constant increase in its incidence and, for now, there …
was first described, there has been a constant increase in its incidence and, for now, there …